Literature DB >> 2082907

Dyslipoproteinaemia of liver disease.

J P Miller.   

Abstract

Hepatic diseases differ from most other causes of secondary dyslipidaemia in that the circulating lipoproteins are not only present in abnormal amounts but they frequently also have abnormal composition, electrophoretic mobility and appearance. Pre-beta and alpha bands can be absent on electrophoresis in all types of liver disease although material in the VLDL and HDL ranges can be isolated in the ultracentrifuge. Cholestatic liver disease has been the most extensively studied and the hyperlipidaemia can be extreme with marked elevations of free cholesterol and phospholipids. This results largely from the presence of LP-X, an abnormal LDL, with a vesicular structure that appears in rouleaux formation under the electron microscope. It is virtually specific for cholestasis and familial LCAT deficiency. The LDL, however, is heterogeneous and may also contain a large triglyceride-rich particle (LP-Y) as well as more normal-looking particles, which are none the less depleted in cholesteryl esters and rich in triglycerides. Indeed, when patients with cholestasis are hypertriglyceridaemic the excess triglyceride is to be found predominantly in these two LDL fractions rather than in VLDL. HDL in cholestasis may contain disc-like particles, similar to those newly secreted by the liver and intestine, as well as more normal-looking spherical particles. In extrahepatic obstruction concentrations of HDL and its major apolipoproteins, apoAI and apoAII, are frequently reduced, although a subfraction rich in apoE is often found. In all but the latest stages of chronic intrahepatic cholestasis due to primary biliary cirrhosis, however, HDL, especially HDL2, concentrations are increased, probably due to the presence of a circulating inhibitor of HL. Many of these lipoprotein changes found in cholestasis resemble those of familial LCAT deficiency, although the hyperlipidaemia is not usually so severe in the latter condition. Indeed, in patients with cholestasis but well-preserved LCAT activity many of the characteristic lipoprotein changes, such as LP-X, LP-Y and discoidal HDL, may not be seen. In acute hepatocellular disease, such as alcoholic or viral hepatitis, it is not unusual for the patient to go through a cholestatic phase and many of the same lipoprotein changes may be seen. In cirrhosis without cholestasis the patients are not usually significantly hyperlipidaemic and in advanced cases cholesterol and apoB levels may be reduced. Although LCAT activity and the proportion of plasma cholesterol esterified may also be markedly reduced, LP-X is not usually seen, possibly because the flux of free cholesterol and phospholipid (lecithin), the LCAT substrates, is relatively low. Discoidal HDLs are often present.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2082907     DOI: 10.1016/s0950-351x(05)80080-1

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  16 in total

1.  Effect of lipoprotein-X on lipid metabolism in rat kidney.

Authors:  K O; M Ly; D Z Fang; J Frohlich; P C Choy
Journal:  Mol Cell Biochem       Date:  1997-08       Impact factor: 3.396

2.  A comprehensive analysis of 12 thrombophilic mutations and related parameters in patients with inflammatory bowel disease: data from Turkey.

Authors:  Serif Yilmaz; Kadim Bayan; Yekta Tüzün; Sabri Batun; Abdullah Altintaş
Journal:  J Thromb Thrombolysis       Date:  2006-12       Impact factor: 2.300

3.  Impaired plasma lipid profiles in acute hepatitis.

Authors:  Libo Luo; Xiangke Pu; Yongzhong Wang; Ning Xu
Journal:  Lipids Health Dis       Date:  2010-01-23       Impact factor: 3.876

4.  Severe hypercholesterolemia associated with decreased hepatic triglyceride lipase activity and pseudohyponatremia in patients after allogeneic stem cell transplantation.

Authors:  Yoshihiro Inamoto; Tamio Teramoto; Koji Shirai; Hideko Tsukamoto; Takaomi Sanda; Koichi Miyamura; Ikuo Yamamori; Noriyuki Hirabayashi; Yoshihisa Kodera
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

5.  Uptake and metabolism of lipoprotein-X in mesangial cells.

Authors:  E G Lynn; P C Choy; A Magil; K O
Journal:  Mol Cell Biochem       Date:  1997-10       Impact factor: 3.396

6.  Serum markers may distinguish biliary atresia from other forms of neonatal cholestasis.

Authors:  Hongtao Wang; James P Malone; Petra Erdmann Gilmore; Alan E Davis; John C Magee; R Reid Townsend; Robert O Heuckeroth
Journal:  J Pediatr Gastroenterol Nutr       Date:  2010-04       Impact factor: 2.839

Review 7.  Metabolism of energy-yielding substrates in patients with liver cirrhosis.

Authors:  M J Müller; K H Böker; O Selberg
Journal:  Clin Investig       Date:  1994-08

8.  Expression patterns and action analysis of genes associated with drug-induced liver diseases during rat liver regeneration.

Authors:  Qian-Ji Ning; Shao-Wei Qin; Cun-Shuan Xu
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

9.  Decreased paraoxonase-1 activity is associated with alterations of high-density lipoprotein particles in chronic liver impairment.

Authors:  Judit Marsillach; Gerard Aragonès; Bharti Mackness; Michael Mackness; Anna Rull; Raúl Beltrán-Debón; Juan Pedro-Botet; Carlos Alonso-Villaverde; Jorge Joven; Jordi Camps
Journal:  Lipids Health Dis       Date:  2010-05-14       Impact factor: 3.876

10.  Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse.

Authors:  Anne Braun; Songwen Zhang; Helena E Miettinen; Shamsah Ebrahim; Teresa M Holm; Eliza Vasile; Mark J Post; Danita M Yoerger; Michael H Picard; Joshua L Krieger; Nancy C Andrews; Michael Simons; Monty Krieger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.